[1]李 楠,夏松青,张勇慧,等.肾益康胶囊联合氯沙坦钾治疗慢性肾炎疗效及对患者肾功能、凝血功能的影响*[J].陕西中医,2019,(6):760-763.
　LI Nan,XIA Songqing,ZHANG Yonghui,et al.Effect of Shenyikang capsule combined with losartan potassium on renal function and coagulation function in patients with chronic nephritis[J].,2019,(6):760-763.
点击复制

肾益康胶囊联合氯沙坦钾治疗慢性肾炎疗效及对患者肾功能、凝血功能的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年6期
页码:
760-763
栏目:
临床研究
出版日期:
2019-06-05

文章信息/Info

Title:
Effect of Shenyikang capsule combined with losartan potassium on renal function and coagulation function in patients with chronic nephritis
文章编号:
DOI:10.3969/j.issn.1000-7369.2019.06.022
作者:
李 楠; 夏松青; 张勇慧; 姚 雷
河南誉美肾病医院（鹤壁456750）
Author(s):
LI Nan; XIA Songqing; ZHANG Yonghui; et al.
Henan Yumei Nephropathy Hospital（Hebi 456750）
关键词:
肾益康胶囊; 氯沙坦钾; 慢性肾炎; 肾功能; 凝血功能; 血管性血友病因子
Keywords:
Key words Shenyikang capsule; Losartan potassium; Chronic nephritis; Renal function; Coagulation function; Von willebrand factor
分类号:
R692.3
文献标志码:
A
摘要:
摘 要 目的：分析肾益康胶囊联合氯沙坦钾治疗慢性肾炎对患者肾功能和凝血功能的影响。方法：选取慢性肾炎患者114例，根据治疗方法分为对照组（口服氯沙坦钾治疗）和观察组（肾益康胶囊联合氯沙坦钾治疗），分析两组患者治疗后的临床疗效。结果：两组治疗前中医症状积分组间比较，差异不具有统计学意义（ P ＞0.05）。观察组治疗后乏力（1.21±0.54）分、肢体浮肿（1.53±0.53）分、腰部酸痛（1.19±0.61）分、胃脘胀满（1.34±0.72）分、食少纳呆（1.32±0.73）分，均低于对照组（ P ＜0.05)。两组治疗前凝血指标、肾功能指标、血管性血友病因子、白细胞介素-18、可溶性血管内皮细胞蛋白C受体水平组间比较，差异不具有统计学意义（ P ＞0.05）。观察组治疗后凝血酶原时间、活化部分凝血活酶时间、凝血酶-Ⅲ水平高于对照组，纤维蛋白原、D-二聚体、24h尿蛋白、vWF、IL-18、sEPCR水平均低于对照组，但血清尿素氮和血清肌酐水平与对照组比较，差异不具有统计学意义（ P ＞0.05）。结论：肾益康胶囊联合氯沙坦钾治疗慢性肾炎可减轻患者临床症状，改善凝血指标，减少蛋白尿，保护肾功能。
Abstract:
Abstract Objective：To analyze the effect of Shenyikang capsule combined with losartan potassium on renal function and coagulation function in patients with chronic nephritis.Methods： 114 patients with chronic nephritis admitted were divided into two groups：control group (treated with oral losartan potassium) and observation group (Shenyikang capsule combined with losartan potassium therapy).To analyze the clinical effect of two groups of patients after treatment.Results：There was no significant difference between the two groups before treatment ( P ＞0.05).In the observation group，the scores of fatigue (1.21±0.54)，limb edema (1.53±0.53)，pain in the waist (1.19±0.61)，stomachache (1.34 ±0.72) and stomachache were(1.32±0.73) .The scores of above were lower than those of the control group ( P ＜0.05).The indexes of coagulation，renal function，von Willebrand factor，interleukin-18 and soluble vascular endothelial cell protein C receptor were compared between the two groups before treatment.The difference was not statistically significant ( P ＞0.05).The levels of APTT,thrombin Ⅲ，fibrinogen，D- dimer，24 hours urine protein and vWF，in the observation group were higher than those in the control group after treatment with prothrombin time, activation and partial thromboplastin time.The level of IL-18,sEPCR was lower than that of the control group，but The levels of serum urea nitrogen and serum creatinine were not significantly different from those of the control group ( P ＞0.05).Conclusion： Shenyikang capsule combined with losartan potassium in the treatment of chronic glomerulonephritis can relieve clinical symptoms improve coagulation index reduce proteinuria and protect renal function.

参考文献/References:

[1] 秦利强,张 卓,徐 智,等.阿托伐他汀联合依那普利及缬沙坦对慢性肾炎患者尿素氮、血脂及炎症因子的影响[J].中国老年学杂志,2016,36(10):2470-2472.
[2]倪志刚.氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者血浆蛋白浓度和IL-1、IL-6、IL-13水平的影响[J].上海医药,2016,37(19):34-37.
[3] 魏文娟,孙 伟.益肾清利活血法治疗慢性肾炎性蛋白尿50例[J].河南中医,2016,36(11):1976-1978.
[4] 李顺民.现代肾脏病学\[M\].北京:中国医药科技出版社,2014:211-212．
[5] 国家中医药管理局.中药新药临床研究指导原则\[M\].北京:中国医药科技出版社,2002:162.
[6] Svetyy LI，Lopukhova VA，Tarasenko IV.Evaluation of pharmacotherapy with perindopril，losartan potassium，and their combination in elderly patients with chronic heart failure[J].Advances in Gerontology，2016，6(1):67-69.
[7] 王 钢.阿托伐他汀联合缬沙坦治疗慢性肾炎的疗效探讨[J].中国处方药,2016,14(3):59-59,60.
[8] 张继锋.黄芪注射液联合氯沙坦钾治疗慢性肾炎临床效果观察[J].北方药学,2017,14(12):93-94.
[9] 邹燕勤,易 岚.慢性肾炎临证辨治撷要[J].江苏中医药,2018,50(6):1-5.〖ZK)〗
[10] 祁爱蓉,文善适,傅 博,等.中医辨证联合雷公藤多苷片治疗慢性肾炎的临床观察[J].云南中医学院学报,2018,41(2):51-54.
[11] 刘丹丹,王祥生.王祥生治疗慢性肾炎学术经验研究[J].世界中西医结合杂志,2016,11(8):1073-1076.
[12] 刘 琴,王红蕾,邓康平,等.贝那普利联合黄葵对慢性肾小球肾炎的治疗效果及安全性评价[J].陕西医学杂志,2018,47(1):96-98,
[13] 张晓丽,张金梅,武文斌,等.肾炎舒颗粒对早期糖尿病肾病患者尿足细胞及肾小管功能的影响[J].山东医药,2016,56(33):75-77.
[14] 赵熹君,潘小萍,段美庆,等.抗凝血酶-Ⅲ检测在慢性肾小球肾炎与泌尿系感染中的比较分析[J].国际免疫学杂志,2016,39(4):358-360.
[15] Vos MB，Ran J，Konomi JV， et al .A randomized，controlled，crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease:[J].Pilot & Feasibility Studies，2018，4(1):109.
[16] 黄 可,刘日阳.儿童过敏性紫癜继发肾损伤中血FIB、D-D和FDP的表达意义研究[J].国际医药卫生导报,2016,22(6):747-749,755.
[17] 王亿平,徐文静,王 东,等.参地颗粒对系膜增生性肾小球肾炎大鼠内皮细胞的干预作用[J].中成药,2017,39(11):2369-2372.
[18] 王亿平,王 东,徐文静,等.参地颗粒对慢性肾炎脾肾亏虚证患者肾小球内皮细胞的干预作用[J].中国中西医结合急救杂志,2016,23(4):360-363.
[19] 沈 燕,陈冬梅,明志兵,等.尿毒症自体动静脉内瘘失功患者血浆sEPCR水平变化及意义[J].山东医药,2017,57(36):84-86.
[20] 刘美兰,马福哲,吴 昊,等.狼疮性肾炎患者血清IL-18、IL-34水平及其意义[J].中国现代医学杂志,2018,28(2):53-56.
[21] 龙 彪,曾冬梅,罗 莉,等.原发性肾病综合征患儿外周血单个核细胞IL-18、Fas mRNA表达变化及其意义[J].山东医药,2017,57(35):77-79.

备注/Memo

备注/Memo:
*河南省医学科技攻关计划项目（2016043901）
更新日期/Last Update: 2019-06-20